According to the results published by a previous study, blood levels of IL-17A and IL-17F were significantly higher in patients with MS than in healthy controls, and IL-17F serum levels and the frequency of relapses were strongly correlated. This evidence concerns the gene IL17A and myeloid sarcoma.